<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363539">
  <stage>Registered</stage>
  <submitdate>23/01/2013</submitdate>
  <approvaldate>4/02/2013</approvaldate>
  <actrnumber>ACTRN12613000133730</actrnumber>
  <trial_identification>
    <studytitle>Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors  </studytitle>
    <scientifictitle>A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym>HMPL-504</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Histologically or cytologically documented, incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy
</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200mg,oral,once daily.
There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.and one cohort contains 21 days.

</interventions>
    <comparator>not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The safety and tolerability of single and multiple doses of HMPL-504 administered to patients,The safety and tolerability variables to be evaluated in this study are adverse events, physical examinations, vital signs ,clinical laboratory evaluations including serum chemistry, hematology , and urinalysis , and electrocardiograms (ECGs) in triplicate,Incidence and nature of DLTs(Dose-Limiting Toxicity),To determine the MTD (Maximum Tolerated Dose).</outcome>
      <timepoint>up to 20 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic Assessments for area under curve (AUC), Cmax and Tmax </outcome>
      <timepoint>Day 1-3 Single Dose and Day 1-21 Steady State</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Signed Informed Consent Form ,locally advanced, or metastatic solid malignancy ;Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1;Male or female patients of child-producing potential must agree to take contraception measures to avoidance of pregnancy during the study and for 90 days after the last day of treatment;
Patients with gastric cancer , NSCLC, colorectal cancer, breast cancer and hepatocellular carcinoma(HCC) are preferred to be enrolled into the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Inadequate hematologic and organ function, defined by the following ;
Clinical significant active infection;
Adverse events from prior anti-cancer therapy that have not resolved to Grade = 1, except for alopecia;
Pregnant or lactating women;
History of myocardial infarction ;
Active or untreated brain metastasis;
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort
An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504).
</concealment>
    <sequence>This is a multiple-center, open-label, dose-escalation study . 
Patients will be assigned to dose levels sequentially in which they are enrolled.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures> There are two stages to this study : a dose-escalation stage and a dose-expansion stage.
The dose-escalation stage is designed to evaluate the safety, tolerability, and pharmacokinetics of HMPL-504 given once every day (QD).
 Once the Maximum Tolerated Dose (MTD) or the recommended phase 2 dose (RPTD)has been established, an additional up to 10 patients will be enrolled in the dose-expansion stage at the MTD or RPTD to better characterize the safety, tolerability and PK variability of the specific HMPL-504 dose. </designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods>The final analysis will be based on patient data collected through study discontinuation or study termination. All analyses will be based on the safety-evaluable population, which is defined as all patients who receive any amount of HMPL-504. All summaries will be presented by assigned dose level.</statisticalmethods>
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>15/02/2012</anticipatedstartdate>
    <actualstartdate>15/02/2012</actualstartdate>
    <anticipatedenddate>30/06/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>25</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA,VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hutchison Medipharma Ltd</primarysponsorname>
    <primarysponsoraddress>Building 4  720 Cai Lun Road Zhangjiang Hi-Tech Park
Shanghai  China 201203  </primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Hutchison Medipharma Ltd</fundingname>
      <fundingaddress>Building 4  720 Cai Lun Road Zhangjiang Hi-Tech Park
Shanghai  China 201203  </fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress>none</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Linear Clinical Research Ltd </othercollaboratorname>
      <othercollaboratoraddress>229 Greenhill Road Dulwich SA 5065</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname> Austin Health
</othercollaboratorname>
      <othercollaboratoraddress> 145 Studley Road PO Box 5555 Heidelberg Victoria  Australia  3084
</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname> Monash  Medical Centre </othercollaboratorname>
      <othercollaboratoraddress> 246 Clayton Road Clayton VIC 3168, Australia</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients with Advanced Solid Tumors.
You may be eligible to join this study if you are aged 18 years or more and have been diagnosed with incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy. Trial details Participants in this trial will be allocated to take Volitinib (HMPL-504) tablets once daily for a period of [a cohort /21 days] at one of six dose levels (100, 200, 400, 600, 800 or 1000 mg/day). Patients will be assigned to dose levels sequentially as they are enrolled. Participants will be assessed for up to 20 months in order to determine safety and tolerability of the treatment. They will also be asked to give blood samples to assess the pharmacokinetics (i.e. action of the drug in the body) over a 21 day period. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>the Bellberry Human Research Ethics </ethicname>
      <ethicaddress> Hospital Avenue,Nedlands Perth 6009 ,Westem Australia</ethicaddress>
      <ethicapprovaldate>31/01/2012</ethicapprovaldate>
      <hrec>2011-09-459-A-1</hrec>
      <ethicsubmitdate>16/01/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress> 145 Studly Road PO Box 5555 Heidelberg Victoria Australia 3084</ethicaddress>
      <ethicapprovaldate>31/01/2012</ethicapprovaldate>
      <hrec>HREC/11/Auston/50</hrec>
      <ethicsubmitdate>13/01/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Hui Gan </name>
      <address>145 Studley Road PO Box 5555 Heidelberg Victoria  Australia  3084
</address>
      <phone>+ 61 3 9496 5354</phone>
      <fax>+ 61 3 9457 6698</fax>
      <email>Hui.Gan@ludwig.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Charlie Qi</name>
      <address>Hutchison MediPharma Limited
Building 4  720 Cai Lun Road  Zhangjiang Hi-Tech Park
Shanghai  China 201203  
</address>
      <phone>  +86 21 5079 0088</phone>
      <fax> 86 21 50793597</fax>
      <email>charlieq@hmplglobal.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Hua Mu</name>
      <address>Hutchison MediPharma Limited
Building 4  720 Cai Lun Road  Zhangjiang Hi-Tech Park
Shanghai  China 201203  
</address>
      <phone>  +86 21 5079 0088</phone>
      <fax> 86 21 50793597</fax>
      <email>HuaMu@hmplglobal.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Tracy Tan</name>
      <address>Hutchison MediPharma Limited
Building 4  720 Cai Lun Road  Zhangjiang Hi-Tech Park
Shanghai  China 201203  
</address>
      <phone> +86 21 5079 0088</phone>
      <fax> 86 21 50793597</fax>
      <email>Tracyt@hmplglobal.com</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>